Articles

Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 30,280 new cases of multiple myeloma will be diagnosed in 2017, and 12,590 deaths will be attributed to the disease. In the past 20 years, mortality rates associated with multiple myeloma have declined. Novel therapies, as well as improvements in autologous hematopoietic stem-cell transplantation (HSCT) procedures and supportive care, have contributed to extended survival for patients with this malignancy.

By Lisa A. Raedler, PhD, RPh, Medical Writer

FDA News & Updates, Bladder Cancer

2018 Third Annual Oncology Guide to New FDA Approvals

Urothelial carcinoma is the most common subtype of bladder cancer, accounting for more than 90% of bladder cancer diagnoses in the United States. In 2017, more than 79,000 bladder cancer cases were diagnosed in the United States, and more than 16,000 people died from this disease. The prognosis is favorable for patients with localized disease, with a 5-year relative survival rate of 78% for all stages of bladder cancer, which decreases to 5% for patients with distant disease.

By Loretta Fala, Medical Writer

FDA News & Updates, Breast Cancer

2018 Third Annual Oncology Guide to New FDA Approvals

Breast cancer affects more women than any other type of cancer, and represents 15% of all new cancer cases in the United States. A total of 252,710 new breast cancer cases were estimated to be diagnosed in 2017, and more than 40,600 deaths. The prognosis worsens for patients with locally advanced breast cancer and even more so for those with metastatic disease.

By Lisa A. Raedler, PhD, RPh, Medical Writer

FDA News & Updates, Leukemia

2018 Third Annual Oncology Guide to New FDA Approvals

Acute myeloid leukemia (AML) is a rare but deadly cancer. Approximately 21,400 new cases of AML were diagnosed in 2017 in the United States, and nearly 10,600 people died from the disease. Approximately 60% to 70% of adults with AML respond to initial treatment with cytotoxic chemotherapy. However, the 5-year survival rate for patients with AML remains poor at approximately 27%.

By Loretta Fala, Medical Writer

FDA News & Updates, Lymphoma

2018 Third Annual Oncology Guide to New FDA Approvals

Diffuse large B-cell lymphoma (DLBCL), a form of cancer that starts in the lymphatic system, is the most common type of non-Hodgkin lymphoma (NHL) in adults. In the United States, approximately 72,000 new cases of NHL are diagnosed annually; more than 20,000 people were estimated to die from the disease in 2017.

By Lisa A. Raedler, PhD, RPh, Medical Writer

FDA News & Updates, Ovarian Cancer

2018 Third Annual Oncology Guide to New FDA Approvals

In ovarian epithelial cancer, fallopian tube cancer, and primary peritoneal cancer, malignant cells form in the tissue covering the ovary or lining the fallopian tube or peritoneum. According to the American Cancer Society, in 2017 more than 22,000 women in the United States were estimated to be diagnosed with these cancers and more than 14,000 to die from them.

Updates on Immunotherapy in Advanced Melanoma

By Meg Barbor, MPH

Melanoma, HOPA Abstracts, HOPA Abstracts & Highlights

TOP - May 2018, Vol 11, No 1

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Jaime Anderson, PharmD, BCOP, reviewed recent efficacy and safety data on immune checkpoint inhibitor regimens in melanoma, and discussed disease-specific characteristics that may guide treatment-planning decisions.

Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years

By Phoebe Starr

Prostate Cancer

TOP - May 2018, Vol 11, No 1

According to the results of 2 separate clinical trials presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide reduced the risk for metastasis and prolonged metastasis-free survival in patients with nonmetastatic castrate-resistant prostate cancer.

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

By Meg Barbor, MPH

Side-Effects Management, Side-Effects Management

TOP - May 2018, Vol 11, No 1

At the 2018 Cancer Survivorship Symposium, Katy K. Tsai, MD, suggested that cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint because of its novel mechanisms of action, extended treatment periods, and unique toxicities.

Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer

Breast Cancer, Side-Effects Management, Side-Effects Management

TOP - May 2018, Vol 11, No 1

Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.

Articles

Page 106 of 289